Boston, Massachusetts
PhaseV announced today that 2025 marked a defining year for the company, highlighted by record revenue growth, expanded global partnerships, and increasing adoption of its artificial intelligence platform across late-stage and enterprise clinical development programs.
Over the past year, PhaseV experienced nearly fivefold revenue growth as pharmaceutical sponsors and contract research organizations moved beyond pilot programs to enterprise-wide use of the company’s AI-driven clinical development platform. Customers increasingly adopted PhaseV’s full suite of solutions, enabling integrated trial design, execution, and optimization.
PhaseV now collaborates with more than 40 biopharma sponsors and CROs worldwide, including seven of the largest global pharmaceutical companies. This growth was further supported by a $50 million Series A financing round completed in 2025, providing capital to accelerate platform expansion and global deployment.
“AI experimentation is no longer enough for the industry,” said Raviv Pryluk, PhD, Chief Executive Officer and Co-Founder of PhaseV. “Sponsors are demanding measurable results. Our focus has been on delivering faster trials, lower costs, and higher confidence in outcomes—and we’re seeing that demand accelerate.”
PhaseV’s platform applies large-scale simulations and predictive modeling to clinical trial planning and execution. Sponsors using the platform have reported significant reductions in trial duration and cost, along with meaningful improvements in trial success rates. The company’s technology supports real-time monitoring, optimized site selection, and advanced patient stratification.
In 2025, PhaseV expanded its proprietary data infrastructure to include more than two million patient-level records, strengthening predictive models across multiple disease areas, including oncology, immunology, neurology, gastrointestinal disorders, and rare diseases.
The company also gained recognition across the healthcare and technology sectors for its contributions to AI-enabled clinical development and shared new research at major scientific and industry conferences throughout the year.
Looking ahead to 2026, PhaseV plans to deepen collaborations with existing partners, broaden adoption across therapeutic areas, and continue enhancing its AI platform to support faster, more efficient, and more reliable drug development. Company leadership will participate in several major industry conferences in early 2026.
About PhaseV
PhaseV develops artificial intelligence solutions designed to improve how clinical trials are designed, executed, and analyzed. Its platform supports a range of trial designs and helps biopharma organizations reduce cost, shorten timelines, and increase the likelihood of clinical success across diverse therapeutic areas.
By